| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urticaria | 73 | 2022 | 84 | 16.160 |
Why?
|
| Bradykinin | 62 | 2022 | 157 | 9.520 |
Why?
|
| Angioedemas, Hereditary | 24 | 2022 | 26 | 9.360 |
Why?
|
| Anti-Allergic Agents | 16 | 2022 | 27 | 6.360 |
Why?
|
| Factor XII | 91 | 2021 | 96 | 5.780 |
Why?
|
| Omalizumab | 22 | 2022 | 24 | 5.240 |
Why?
|
| Complement C1 Inhibitor Protein | 23 | 2022 | 24 | 5.200 |
Why?
|
| Angioedema | 30 | 2021 | 41 | 4.740 |
Why?
|
| Basophils | 47 | 2021 | 57 | 4.420 |
Why?
|
| Prekallikrein | 52 | 2021 | 66 | 4.040 |
Why?
|
| Kininogen, High-Molecular-Weight | 20 | 2020 | 23 | 3.680 |
Why?
|
| Histamine Release | 45 | 2020 | 47 | 3.230 |
Why?
|
| Kinins | 29 | 2016 | 109 | 2.690 |
Why?
|
| Kininogens | 47 | 2021 | 88 | 2.590 |
Why?
|
| Antibodies, Anti-Idiotypic | 14 | 2014 | 43 | 2.470 |
Why?
|
| Endothelium, Vascular | 23 | 2021 | 371 | 2.390 |
Why?
|
| Mast Cells | 27 | 2021 | 113 | 2.340 |
Why?
|
| Kallikreins | 57 | 2021 | 323 | 2.320 |
Why?
|
| Chronic Disease | 46 | 2022 | 1330 | 2.290 |
Why?
|
| Complement System Proteins | 12 | 2021 | 135 | 2.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 10 | 2017 | 151 | 1.910 |
Why?
|
| Histamine Antagonists | 6 | 2019 | 22 | 1.820 |
Why?
|
| Humans | 263 | 2022 | 68618 | 1.820 |
Why?
|
| Blood Coagulation | 26 | 2021 | 123 | 1.810 |
Why?
|
| Cyclosporine | 8 | 2019 | 121 | 1.720 |
Why?
|
| Immunoglobulin E | 27 | 2019 | 91 | 1.710 |
Why?
|
| Fibrinolysis | 20 | 2022 | 55 | 1.600 |
Why?
|
| Hyaluronan Receptors | 10 | 2003 | 142 | 1.510 |
Why?
|
| Skin | 14 | 2019 | 451 | 1.490 |
Why?
|
| Membrane Glycoproteins | 12 | 2004 | 370 | 1.370 |
Why?
|
| Thrombosis | 3 | 2021 | 218 | 1.250 |
Why?
|
| Autoantibodies | 16 | 2019 | 434 | 1.250 |
Why?
|
| Complement Activation | 15 | 2020 | 145 | 1.220 |
Why?
|
| Anaphylaxis | 6 | 2020 | 43 | 1.220 |
Why?
|
| Histamine H1 Antagonists | 10 | 2018 | 22 | 1.160 |
Why?
|
| Endothelial Cells | 9 | 2021 | 384 | 1.120 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 2 | 2017 | 3 | 1.110 |
Why?
|
| Antibodies, Monoclonal | 11 | 2021 | 511 | 1.050 |
Why?
|
| Lymphokines | 13 | 1998 | 49 | 1.030 |
Why?
|
| Receptors, Complement | 12 | 2004 | 58 | 0.970 |
Why?
|
| Receptors, IgE | 10 | 2019 | 22 | 0.960 |
Why?
|
| Complement C1 Inactivator Proteins | 17 | 2013 | 19 | 0.880 |
Why?
|
| Factor XIIa | 12 | 2014 | 12 | 0.860 |
Why?
|
| HSP90 Heat-Shock Proteins | 6 | 2016 | 46 | 0.850 |
Why?
|
| Chemokines | 6 | 2001 | 119 | 0.830 |
Why?
|
| Immunoglobulin G | 11 | 2017 | 481 | 0.810 |
Why?
|
| Pruritus | 6 | 2018 | 35 | 0.810 |
Why?
|
| Immunity, Innate | 3 | 2016 | 156 | 0.790 |
Why?
|
| Plasma Kallikrein | 3 | 2021 | 3 | 0.780 |
Why?
|
| Therapies, Investigational | 1 | 2020 | 6 | 0.740 |
Why?
|
| Zinc | 12 | 2005 | 73 | 0.720 |
Why?
|
| Laryngeal Edema | 1 | 2020 | 1 | 0.710 |
Why?
|
| Biomarkers, Tumor | 11 | 1998 | 508 | 0.710 |
Why?
|
| Shock | 1 | 2020 | 28 | 0.700 |
Why?
|
| Hereditary Angioedema Types I and II | 3 | 2016 | 3 | 0.700 |
Why?
|
| Biological Products | 1 | 2021 | 78 | 0.690 |
Why?
|
| Hypersensitivity | 10 | 2004 | 52 | 0.690 |
Why?
|
| Autoimmune Diseases | 4 | 2008 | 186 | 0.690 |
Why?
|
| Hypotension | 2 | 2020 | 74 | 0.690 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2014 | 202 | 0.690 |
Why?
|
| Immunosuppressive Agents | 5 | 2014 | 514 | 0.660 |
Why?
|
| Cytokines | 9 | 2002 | 866 | 0.660 |
Why?
|
| Renin | 6 | 2013 | 96 | 0.650 |
Why?
|
| Cells, Cultured | 22 | 2016 | 2673 | 0.650 |
Why?
|
| Estrogens | 4 | 2021 | 173 | 0.640 |
Why?
|
| Interleukin-1 | 2 | 2016 | 86 | 0.630 |
Why?
|
| Peptide Fragments | 16 | 2020 | 483 | 0.630 |
Why?
|
| Fumarates | 3 | 2013 | 28 | 0.630 |
Why?
|
| Mitochondrial Proteins | 12 | 2021 | 113 | 0.630 |
Why?
|
| Keratins | 7 | 2005 | 48 | 0.620 |
Why?
|
| Amides | 4 | 2013 | 86 | 0.620 |
Why?
|
| Inflammation | 12 | 2016 | 1030 | 0.610 |
Why?
|
| Eosinophils | 10 | 2007 | 60 | 0.600 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2013 | 38 | 0.590 |
Why?
|
| Molecular Weight | 39 | 2001 | 358 | 0.590 |
Why?
|
| Signal Transduction | 6 | 2017 | 2689 | 0.570 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 45 | 0.560 |
Why?
|
| Vibration | 2 | 2016 | 32 | 0.550 |
Why?
|
| Animals | 37 | 2020 | 20881 | 0.540 |
Why?
|
| Carrier Proteins | 12 | 2021 | 597 | 0.540 |
Why?
|
| Histamine | 21 | 2009 | 52 | 0.520 |
Why?
|
| Mutation, Missense | 1 | 2016 | 112 | 0.520 |
Why?
|
| Estradiol | 1 | 2016 | 176 | 0.520 |
Why?
|
| Allergens | 7 | 2008 | 54 | 0.500 |
Why?
|
| Hydroxyzine | 5 | 2008 | 6 | 0.500 |
Why?
|
| Plasminogen | 14 | 2022 | 28 | 0.500 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2015 | 56 | 0.490 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 167 | 0.490 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2016 | 626 | 0.480 |
Why?
|
| Protein Binding | 12 | 2016 | 1027 | 0.470 |
Why?
|
| Factor XI | 14 | 2019 | 14 | 0.460 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 13 | 2015 | 507 | 0.460 |
Why?
|
| Asthma | 7 | 2021 | 345 | 0.450 |
Why?
|
| Chemotactic Factors | 5 | 1995 | 14 | 0.450 |
Why?
|
| Enzyme Activation | 24 | 2016 | 791 | 0.440 |
Why?
|
| Capillary Permeability | 4 | 2021 | 69 | 0.440 |
Why?
|
| Interleukin-3 | 5 | 2003 | 63 | 0.440 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 244 | 0.410 |
Why?
|
| Polysaccharides | 4 | 2014 | 176 | 0.410 |
Why?
|
| Umbilical Veins | 10 | 2003 | 54 | 0.400 |
Why?
|
| Cold Temperature | 12 | 2021 | 90 | 0.400 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 13 | 2009 | 272 | 0.400 |
Why?
|
| Edema | 3 | 2020 | 66 | 0.400 |
Why?
|
| Methotrexate | 2 | 2008 | 91 | 0.380 |
Why?
|
| Amino Acid Sequence | 13 | 2005 | 1083 | 0.370 |
Why?
|
| Adult | 35 | 2021 | 21403 | 0.370 |
Why?
|
| Treatment Outcome | 12 | 2019 | 7029 | 0.370 |
Why?
|
| Female | 43 | 2022 | 38074 | 0.360 |
Why?
|
| Male | 40 | 2021 | 37321 | 0.360 |
Why?
|
| Biosynthetic Pathways | 1 | 2010 | 15 | 0.360 |
Why?
|
| Peptides | 7 | 1996 | 455 | 0.360 |
Why?
|
| Recombinant Proteins | 10 | 2021 | 742 | 0.360 |
Why?
|
| Amyloid beta-Peptides | 3 | 2002 | 191 | 0.340 |
Why?
|
| Blood Coagulation Factors | 9 | 2020 | 44 | 0.340 |
Why?
|
| Kallikrein-Kinin System | 3 | 2021 | 18 | 0.340 |
Why?
|
| Blood Platelets | 6 | 1999 | 284 | 0.330 |
Why?
|
| Complement C2 | 4 | 2005 | 9 | 0.320 |
Why?
|
| Kinetics | 21 | 2003 | 1047 | 0.320 |
Why?
|
| Complement C5a | 4 | 2005 | 15 | 0.320 |
Why?
|
| Fibrinolysin | 11 | 2010 | 33 | 0.320 |
Why?
|
| Hypersensitivity, Immediate | 4 | 1998 | 13 | 0.320 |
Why?
|
| Vasodilator Agents | 2 | 2010 | 138 | 0.310 |
Why?
|
| Leukocytes, Mononuclear | 5 | 1996 | 124 | 0.310 |
Why?
|
| Terfenadine | 2 | 2005 | 4 | 0.300 |
Why?
|
| Blood Proteins | 6 | 2002 | 94 | 0.300 |
Why?
|
| Middle Aged | 26 | 2021 | 21147 | 0.300 |
Why?
|
| Epithelial Cells | 1 | 2010 | 431 | 0.300 |
Why?
|
| Interleukin-8 | 4 | 1996 | 71 | 0.290 |
Why?
|
| Factor XIa | 3 | 2016 | 3 | 0.260 |
Why?
|
| Double-Blind Method | 7 | 2017 | 1738 | 0.260 |
Why?
|
| Complement C1q | 4 | 2016 | 18 | 0.260 |
Why?
|
| Biotinylation | 5 | 2004 | 27 | 0.250 |
Why?
|
| Calcineurin Inhibitors | 1 | 2005 | 24 | 0.250 |
Why?
|
| Estrogen Receptor beta | 1 | 2005 | 19 | 0.250 |
Why?
|
| Muscle Proteins | 1 | 2005 | 94 | 0.250 |
Why?
|
| Thyroglobulin | 2 | 2009 | 17 | 0.250 |
Why?
|
| Proteolysis | 4 | 2020 | 97 | 0.240 |
Why?
|
| Kaolin | 10 | 2020 | 23 | 0.240 |
Why?
|
| Blotting, Western | 6 | 2009 | 954 | 0.240 |
Why?
|
| Cell Membrane | 5 | 2004 | 525 | 0.240 |
Why?
|
| Child | 10 | 2022 | 6405 | 0.240 |
Why?
|
| Quality of Life | 4 | 2022 | 1515 | 0.240 |
Why?
|
| Autoimmunity | 5 | 2021 | 118 | 0.240 |
Why?
|
| Models, Biological | 3 | 2008 | 981 | 0.240 |
Why?
|
| Adolescent | 14 | 2017 | 8912 | 0.240 |
Why?
|
| Estrogen Receptor alpha | 1 | 2005 | 65 | 0.240 |
Why?
|
| Binding, Competitive | 7 | 2002 | 165 | 0.240 |
Why?
|
| Thyroid Gland | 2 | 2009 | 67 | 0.240 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2005 | 144 | 0.230 |
Why?
|
| Heparitin Sulfate | 1 | 2003 | 20 | 0.230 |
Why?
|
| Monocytes | 6 | 1998 | 210 | 0.230 |
Why?
|
| Lymphocytes | 5 | 2001 | 228 | 0.230 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 2 | 2021 | 3 | 0.230 |
Why?
|
| Kallidin | 3 | 1989 | 9 | 0.220 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2005 | 317 | 0.220 |
Why?
|
| Time Factors | 11 | 2017 | 4655 | 0.210 |
Why?
|
| Molecular Sequence Data | 9 | 2002 | 1447 | 0.210 |
Why?
|
| Chromatography, Affinity | 9 | 2005 | 73 | 0.200 |
Why?
|
| Viral Structural Proteins | 1 | 2021 | 10 | 0.200 |
Why?
|
| Lysine | 1 | 2022 | 96 | 0.200 |
Why?
|
| Antigens, Viral | 1 | 2021 | 35 | 0.200 |
Why?
|
| Enzyme Precursors | 7 | 1998 | 27 | 0.200 |
Why?
|
| T-Lymphocytes | 4 | 2001 | 597 | 0.200 |
Why?
|
| Complement Pathway, Classical | 5 | 1986 | 22 | 0.200 |
Why?
|
| Immunoblotting | 5 | 1998 | 254 | 0.200 |
Why?
|
| Hereditary Angioedema Type III | 1 | 2021 | 3 | 0.200 |
Why?
|
| Binding Sites | 11 | 2004 | 631 | 0.190 |
Why?
|
| Receptors, Chemokine | 1 | 2001 | 26 | 0.190 |
Why?
|
| Pressure | 1 | 2002 | 252 | 0.190 |
Why?
|
| Astrocytes | 1 | 2003 | 270 | 0.190 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1553 | 0.190 |
Why?
|
| Cardiovascular Agents | 1 | 2021 | 82 | 0.190 |
Why?
|
| Chemokine CCL2 | 7 | 2005 | 101 | 0.190 |
Why?
|
| Growth Substances | 2 | 1993 | 77 | 0.190 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2020 | 34 | 0.180 |
Why?
|
| Skin Tests | 6 | 2005 | 30 | 0.180 |
Why?
|
| Thrombin | 3 | 1999 | 117 | 0.180 |
Why?
|
| Young Adult | 6 | 2021 | 5717 | 0.170 |
Why?
|
| Physical Exertion | 5 | 1984 | 75 | 0.170 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 1999 | 7 | 0.170 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 170 | 0.170 |
Why?
|
| Syk Kinase | 1 | 2019 | 10 | 0.170 |
Why?
|
| Complement C4a | 2 | 2010 | 2 | 0.170 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 89 | 0.170 |
Why?
|
| Ribonucleases | 2 | 1996 | 25 | 0.170 |
Why?
|
| Lung | 5 | 2003 | 849 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 848 | 0.170 |
Why?
|
| Drug Therapy, Combination | 4 | 2015 | 649 | 0.170 |
Why?
|
| Glutamic Acid | 1 | 2022 | 332 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2014 | 1745 | 0.160 |
Why?
|
| Genetic Therapy | 1 | 2020 | 291 | 0.160 |
Why?
|
| Influenza, Human | 2 | 1996 | 79 | 0.160 |
Why?
|
| Chemotaxis | 6 | 1998 | 38 | 0.160 |
Why?
|
| Drug Hypersensitivity | 3 | 2015 | 35 | 0.160 |
Why?
|
| Histamine H2 Antagonists | 2 | 2016 | 45 | 0.160 |
Why?
|
| Terminology as Topic | 1 | 2019 | 141 | 0.160 |
Why?
|
| Receptors, Cytokine | 2 | 1998 | 19 | 0.160 |
Why?
|
| Antibodies | 6 | 2003 | 241 | 0.160 |
Why?
|
| Diagnosis, Differential | 5 | 2012 | 1140 | 0.160 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 219 | 0.150 |
Why?
|
| Carboxypeptidases | 2 | 1989 | 8 | 0.150 |
Why?
|
| Thromboplastin | 3 | 1996 | 21 | 0.150 |
Why?
|
| Th2 Cells | 4 | 2007 | 48 | 0.150 |
Why?
|
| Mutation | 2 | 2015 | 1213 | 0.150 |
Why?
|
| Receptors, Cell Surface | 3 | 2004 | 248 | 0.150 |
Why?
|
| Rhinitis, Allergic, Seasonal | 2 | 2004 | 22 | 0.150 |
Why?
|
| Complement C1 | 3 | 2014 | 4 | 0.150 |
Why?
|
| Receptors, Peptide | 1 | 1997 | 32 | 0.150 |
Why?
|
| Agranulocytosis | 1 | 2017 | 15 | 0.140 |
Why?
|
| Aged | 9 | 2017 | 14862 | 0.140 |
Why?
|
| Chromatography, Gel | 13 | 2004 | 79 | 0.140 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1997 | 73 | 0.140 |
Why?
|
| Ligands | 3 | 2004 | 317 | 0.140 |
Why?
|
| Hypersensitivity, Delayed | 2 | 1994 | 19 | 0.140 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2016 | 26 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2004 | 186 | 0.140 |
Why?
|
| Macromolecular Substances | 7 | 2002 | 122 | 0.140 |
Why?
|
| Common Cold | 1 | 1996 | 8 | 0.140 |
Why?
|
| Factor IX | 1 | 1996 | 3 | 0.140 |
Why?
|
| Hemorrhagic Disorders | 1 | 1996 | 7 | 0.140 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2015 | 9 | 0.130 |
Why?
|
| Desensitization, Immunologic | 1 | 2015 | 25 | 0.130 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2015 | 58 | 0.130 |
Why?
|
| G(M1) Ganglioside | 1 | 2014 | 8 | 0.120 |
Why?
|
| Risk Factors | 2 | 2015 | 5731 | 0.120 |
Why?
|
| Sirolimus | 1 | 2015 | 118 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 567 | 0.120 |
Why?
|
| Nerve Growth Factor | 1 | 2014 | 54 | 0.120 |
Why?
|
| In Vitro Techniques | 9 | 2003 | 765 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2016 | 204 | 0.120 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2014 | 100 | 0.120 |
Why?
|
| Th1 Cells | 2 | 2007 | 101 | 0.120 |
Why?
|
| Serine Endopeptidases | 2 | 1996 | 50 | 0.120 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 2 | 2004 | 14 | 0.120 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2016 | 296 | 0.110 |
Why?
|
| Antifibrinolytic Agents | 1 | 2014 | 52 | 0.110 |
Why?
|
| 3-Mercaptopropionic Acid | 1 | 2013 | 1 | 0.110 |
Why?
|
| Dermatitis, Contact | 3 | 1997 | 14 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 1753 | 0.110 |
Why?
|
| Analgesics | 1 | 2014 | 118 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 322 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2015 | 215 | 0.110 |
Why?
|
| Immune Sera | 2 | 2007 | 30 | 0.110 |
Why?
|
| Recurrence | 3 | 2015 | 948 | 0.110 |
Why?
|
| Incidence | 2 | 2014 | 1603 | 0.110 |
Why?
|
| Chromatography, Ion Exchange | 7 | 1996 | 73 | 0.110 |
Why?
|
| Rats | 7 | 2014 | 5300 | 0.100 |
Why?
|
| Dose-Response Relationship, Immunologic | 3 | 2005 | 31 | 0.100 |
Why?
|
| Nasal Mucosa | 4 | 1996 | 68 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 240 | 0.100 |
Why?
|
| Connective Tissue | 1 | 1992 | 61 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 189 | 0.100 |
Why?
|
| Hypertension | 2 | 2011 | 1535 | 0.100 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2011 | 8 | 0.100 |
Why?
|
| Chemokine CCL5 | 3 | 1996 | 23 | 0.100 |
Why?
|
| Biological Factors | 1 | 1991 | 11 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2013 | 323 | 0.090 |
Why?
|
| Biopsy | 3 | 2002 | 540 | 0.090 |
Why?
|
| Cholinergic Fibers | 2 | 1981 | 27 | 0.090 |
Why?
|
| Neutrophils | 6 | 1998 | 204 | 0.090 |
Why?
|
| Receptor, Bradykinin B1 | 1 | 2010 | 25 | 0.090 |
Why?
|
| Adjuvants, Immunologic | 1 | 2010 | 63 | 0.090 |
Why?
|
| Androgens | 1 | 2010 | 41 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2011 | 155 | 0.090 |
Why?
|
| Airway Obstruction | 1 | 2010 | 49 | 0.090 |
Why?
|
| Medical Records | 1 | 2010 | 121 | 0.090 |
Why?
|
| Leukocytes | 2 | 2005 | 99 | 0.090 |
Why?
|
| Consensus | 2 | 2022 | 211 | 0.090 |
Why?
|
| Antihypertensive Agents | 2 | 2011 | 498 | 0.090 |
Why?
|
| Receptor, Bradykinin B2 | 1 | 2010 | 75 | 0.090 |
Why?
|
| Rabbits | 5 | 2010 | 509 | 0.090 |
Why?
|
| Hemolysis | 5 | 2021 | 39 | 0.090 |
Why?
|
| Binding Sites, Antibody | 1 | 1989 | 34 | 0.090 |
Why?
|
| Leukotriene Antagonists | 2 | 2016 | 13 | 0.090 |
Why?
|
| Pancreatic Elastase | 1 | 1989 | 33 | 0.080 |
Why?
|
| Complement Inactivating Agents | 1 | 2010 | 56 | 0.080 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 334 | 0.080 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2001 | 48 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2077 | 0.080 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2010 | 124 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 1851 | 0.080 |
Why?
|
| Renin-Angiotensin System | 3 | 2010 | 79 | 0.080 |
Why?
|
| Catalysis | 1 | 2009 | 123 | 0.080 |
Why?
|
| Respiratory Mucosa | 2 | 2006 | 52 | 0.080 |
Why?
|
| alpha-2-Antiplasmin | 1 | 2008 | 4 | 0.080 |
Why?
|
| Colony-Stimulating Factors | 1 | 1988 | 19 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2021 | 3705 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 123 | 0.080 |
Why?
|
| Interferon-gamma | 2 | 2007 | 241 | 0.080 |
Why?
|
| Iodine Radioisotopes | 3 | 1999 | 119 | 0.080 |
Why?
|
| Diphenhydramine | 2 | 2005 | 13 | 0.080 |
Why?
|
| Blood Pressure | 3 | 2011 | 1451 | 0.070 |
Why?
|
| Plasma | 2 | 1999 | 58 | 0.070 |
Why?
|
| Prednisone | 2 | 2004 | 104 | 0.070 |
Why?
|
| Radioimmunoassay | 3 | 1993 | 164 | 0.070 |
Why?
|
| Leukotrienes | 1 | 2007 | 13 | 0.070 |
Why?
|
| Cyproheptadine | 3 | 1984 | 6 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 2550 | 0.070 |
Why?
|
| Interleukin-4 | 1 | 2007 | 69 | 0.070 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2006 | 16 | 0.070 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2006 | 15 | 0.070 |
Why?
|
| Hemothorax | 1 | 2006 | 9 | 0.070 |
Why?
|
| Neoplasms | 2 | 2016 | 1667 | 0.070 |
Why?
|
| Lysine Carboxypeptidase | 1 | 1986 | 2 | 0.070 |
Why?
|
| Synovial Membrane | 1 | 1986 | 23 | 0.070 |
Why?
|
| Autoantigens | 1 | 2007 | 91 | 0.070 |
Why?
|
| Pneumothorax | 1 | 2006 | 42 | 0.070 |
Why?
|
| Eosinophilia | 1 | 2006 | 47 | 0.070 |
Why?
|
| Pleural Effusion | 1 | 2006 | 74 | 0.070 |
Why?
|
| Proteoglycans | 2 | 1997 | 103 | 0.070 |
Why?
|
| Heparin | 3 | 1997 | 205 | 0.070 |
Why?
|
| Dextran Sulfate | 3 | 1992 | 88 | 0.060 |
Why?
|
| alpha-Macroglobulins | 1 | 1985 | 8 | 0.060 |
Why?
|
| Basophil Degranulation Test | 1 | 2005 | 1 | 0.060 |
Why?
|
| Blood Coagulation Disorders | 5 | 1979 | 45 | 0.060 |
Why?
|
| Cell Degranulation | 2 | 2009 | 24 | 0.060 |
Why?
|
| Osmolar Concentration | 1 | 2005 | 134 | 0.060 |
Why?
|
| Factor XI Deficiency | 5 | 1996 | 6 | 0.060 |
Why?
|
| Emergency Treatment | 1 | 2005 | 52 | 0.060 |
Why?
|
| Biomarkers | 2 | 2021 | 1593 | 0.060 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1986 | 157 | 0.060 |
Why?
|
| Blood Coagulation Tests | 3 | 1989 | 31 | 0.060 |
Why?
|
| Eucalyptus | 1 | 2004 | 3 | 0.060 |
Why?
|
| Paranasal Sinuses | 1 | 2006 | 165 | 0.060 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2004 | 6 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 150 | 0.060 |
Why?
|
| Drug Eruptions | 1 | 1984 | 16 | 0.060 |
Why?
|
| Laryngitis | 1 | 2004 | 12 | 0.060 |
Why?
|
| beta-Thromboglobulin | 2 | 1996 | 7 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 147 | 0.060 |
Why?
|
| Irritants | 1 | 2004 | 10 | 0.060 |
Why?
|
| Neurons | 1 | 2010 | 881 | 0.060 |
Why?
|
| Protein Precursors | 4 | 1992 | 105 | 0.060 |
Why?
|
| Heparin Lyase | 1 | 2003 | 2 | 0.060 |
Why?
|
| Precipitin Tests | 1 | 2004 | 88 | 0.060 |
Why?
|
| Parasympathetic Nervous System | 2 | 1981 | 14 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2004 | 100 | 0.060 |
Why?
|
| Tacrolimus | 1 | 2005 | 127 | 0.060 |
Why?
|
| Isoflurophate | 6 | 1982 | 9 | 0.060 |
Why?
|
| Steroids | 1 | 2004 | 84 | 0.060 |
Why?
|
| Acute Disease | 1 | 2005 | 658 | 0.060 |
Why?
|
| Microcirculation | 1 | 2003 | 77 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 3 | 2010 | 852 | 0.060 |
Why?
|
| Rhinitis | 2 | 2004 | 383 | 0.060 |
Why?
|
| Chemokines, CC | 2 | 2004 | 18 | 0.060 |
Why?
|
| Serpins | 1 | 2005 | 205 | 0.050 |
Why?
|
| Methacholine Compounds | 4 | 1985 | 7 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 772 | 0.050 |
Why?
|
| Disease | 2 | 2013 | 41 | 0.050 |
Why?
|
| Factor VII | 1 | 1982 | 8 | 0.050 |
Why?
|
| Prevalence | 2 | 2021 | 1619 | 0.050 |
Why?
|
| Membrane Proteins | 3 | 2001 | 617 | 0.050 |
Why?
|
| Factor XII Deficiency | 3 | 1996 | 5 | 0.050 |
Why?
|
| Chromatography | 2 | 2020 | 47 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2005 | 1200 | 0.050 |
Why?
|
| Protein Conformation | 2 | 1997 | 362 | 0.050 |
Why?
|
| Nasal Polyps | 1 | 2004 | 184 | 0.050 |
Why?
|
| Complement C5 | 1 | 2002 | 3 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2006 | 1664 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 201 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1988 | 756 | 0.050 |
Why?
|
| Shear Strength | 1 | 2021 | 15 | 0.050 |
Why?
|
| Cell-Free System | 3 | 1996 | 43 | 0.050 |
Why?
|
| Permeability | 1 | 2021 | 131 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2019 | 420 | 0.050 |
Why?
|
| Spirometry | 2 | 2015 | 47 | 0.050 |
Why?
|
| Dextrans | 3 | 1989 | 33 | 0.050 |
Why?
|
| Substrate Specificity | 3 | 1988 | 234 | 0.050 |
Why?
|
| Antibodies, Blocking | 1 | 2001 | 17 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 1997 | 381 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2001 | 97 | 0.050 |
Why?
|
| Antigen Presentation | 1 | 2001 | 76 | 0.050 |
Why?
|
| Cell Line | 4 | 2001 | 1752 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2021 | 274 | 0.050 |
Why?
|
| Research Design | 1 | 2004 | 729 | 0.040 |
Why?
|
| Pollen | 2 | 1992 | 6 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 1993 | 532 | 0.040 |
Why?
|
| Plastics | 1 | 2020 | 25 | 0.040 |
Why?
|
| Electrophoresis, Disc | 8 | 1977 | 11 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2001 | 238 | 0.040 |
Why?
|
| Mice | 5 | 2010 | 8474 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 137 | 0.040 |
Why?
|
| Guinea Pigs | 3 | 1993 | 124 | 0.040 |
Why?
|
| Temperature | 3 | 1986 | 341 | 0.040 |
Why?
|
| Eosinophil Granule Proteins | 2 | 1996 | 5 | 0.040 |
Why?
|
| Thyroid Diseases | 1 | 1999 | 33 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 1174 | 0.040 |
Why?
|
| Drug Interactions | 2 | 2011 | 289 | 0.040 |
Why?
|
| Hydrolysis | 2 | 1989 | 144 | 0.040 |
Why?
|
| Sinusitis | 1 | 2004 | 432 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2020 | 326 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2005 | 2455 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 3 | 1992 | 196 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2019 | 397 | 0.040 |
Why?
|
| Macroglobulins | 2 | 1974 | 3 | 0.040 |
Why?
|
| Indicators and Reagents | 2 | 1988 | 63 | 0.040 |
Why?
|
| Immunoglobulin M | 2 | 1988 | 172 | 0.040 |
Why?
|
| beta-N-Acetylhexosaminidases | 1 | 1997 | 10 | 0.040 |
Why?
|
| Plasminogen Activators | 4 | 1979 | 19 | 0.040 |
Why?
|
| Complement Pathway, Alternative | 3 | 1983 | 69 | 0.040 |
Why?
|
| Placebos | 1 | 2017 | 195 | 0.040 |
Why?
|
| Blood Cells | 1 | 1997 | 27 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 1976 | 39 | 0.040 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 16 | 0.040 |
Why?
|
| Oligopeptides | 2 | 1992 | 152 | 0.030 |
Why?
|
| Cell Fractionation | 1 | 1996 | 34 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 1986 | 618 | 0.030 |
Why?
|
| Peptide Hydrolases | 2 | 1988 | 82 | 0.030 |
Why?
|
| Mucus | 1 | 1996 | 33 | 0.030 |
Why?
|
| Influenza A virus | 1 | 1996 | 13 | 0.030 |
Why?
|
| Tryptases | 1 | 1996 | 3 | 0.030 |
Why?
|
| Chymases | 1 | 1996 | 5 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 2334 | 0.030 |
Why?
|
| Sodium Dodecyl Sulfate | 3 | 1989 | 24 | 0.030 |
Why?
|
| Contrast Media | 1 | 1979 | 595 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2015 | 9 | 0.030 |
Why?
|
| Depression, Chemical | 1 | 1995 | 29 | 0.030 |
Why?
|
| Neurites | 1 | 2014 | 18 | 0.030 |
Why?
|
| PC12 Cells | 1 | 2014 | 36 | 0.030 |
Why?
|
| Immunization, Passive | 3 | 1981 | 24 | 0.030 |
Why?
|
| Indole Alkaloids | 1 | 2014 | 18 | 0.030 |
Why?
|
| Models, Molecular | 1 | 1997 | 546 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 411 | 0.030 |
Why?
|
| Dimerization | 1 | 2014 | 99 | 0.030 |
Why?
|
| Carbazoles | 1 | 2014 | 46 | 0.030 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1974 | 61 | 0.030 |
Why?
|
| Phosphates | 1 | 1994 | 72 | 0.030 |
Why?
|
| Drug Synergism | 3 | 1988 | 260 | 0.030 |
Why?
|
| Health | 1 | 2013 | 26 | 0.030 |
Why?
|
| Receptors, Bradykinin | 1 | 2013 | 50 | 0.030 |
Why?
|
| Blood | 1 | 1973 | 40 | 0.030 |
Why?
|
| Endothelium | 1 | 2013 | 98 | 0.030 |
Why?
|
| Autoradiography | 2 | 1993 | 94 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 2791 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 3 | 1985 | 57 | 0.030 |
Why?
|
| Bradykinin B2 Receptor Antagonists | 1 | 2013 | 13 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2013 | 38 | 0.030 |
Why?
|
| Amino Acid Chloromethyl Ketones | 2 | 1983 | 24 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 1040 | 0.030 |
Why?
|
| Antigen-Antibody Complex | 2 | 1984 | 175 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1994 | 397 | 0.030 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1992 | 60 | 0.030 |
Why?
|
| Expert Testimony | 1 | 2012 | 47 | 0.030 |
Why?
|
| Membranes, Artificial | 1 | 1993 | 88 | 0.030 |
Why?
|
| Pertussis Toxin | 1 | 1992 | 72 | 0.030 |
Why?
|
| International Cooperation | 1 | 2012 | 88 | 0.030 |
Why?
|
| Plateletpheresis | 1 | 1992 | 1 | 0.030 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 1992 | 7 | 0.030 |
Why?
|
| Immunodiffusion | 3 | 1983 | 19 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 1993 | 174 | 0.030 |
Why?
|
| Chlorides | 2 | 1994 | 68 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2013 | 382 | 0.020 |
Why?
|
| Isoelectric Focusing | 5 | 1974 | 42 | 0.020 |
Why?
|
| Interleukin-5 | 2 | 2004 | 14 | 0.020 |
Why?
|
| Germany | 1 | 2011 | 67 | 0.020 |
Why?
|
| Respiratory Function Tests | 2 | 2001 | 123 | 0.020 |
Why?
|
| Streptokinase | 3 | 1979 | 23 | 0.020 |
Why?
|
| Self Administration | 1 | 2013 | 419 | 0.020 |
Why?
|
| Biological Availability | 1 | 2011 | 79 | 0.020 |
Why?
|
| Spectrophotometry | 2 | 1988 | 54 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2011 | 42 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2011 | 107 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2010 | 73 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1034 | 0.020 |
Why?
|
| Receptor, trkB | 1 | 2010 | 27 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 95 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2010 | 39 | 0.020 |
Why?
|
| Edetic Acid | 2 | 1983 | 29 | 0.020 |
Why?
|
| Chromatography, DEAE-Cellulose | 3 | 1975 | 14 | 0.020 |
Why?
|
| Immunoelectrophoresis | 2 | 1981 | 16 | 0.020 |
Why?
|
| Antibody Affinity | 1 | 1989 | 26 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1989 | 98 | 0.020 |
Why?
|
| Streptodornase and Streptokinase | 1 | 1989 | 1 | 0.020 |
Why?
|
| Epitopes | 2 | 2001 | 146 | 0.020 |
Why?
|
| Indicator Dilution Techniques | 1 | 1989 | 8 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2010 | 109 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 392 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2010 | 250 | 0.020 |
Why?
|
| Risk | 1 | 2010 | 563 | 0.020 |
Why?
|
| Calcium | 1 | 1993 | 929 | 0.020 |
Why?
|
| Acetylcholine | 2 | 1980 | 64 | 0.020 |
Why?
|
| Myeloma Proteins | 1 | 1988 | 7 | 0.020 |
Why?
|
| Hot Temperature | 3 | 1988 | 152 | 0.020 |
Why?
|
| Down Syndrome | 1 | 2010 | 120 | 0.020 |
Why?
|
| Memory | 1 | 2010 | 214 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 3259 | 0.020 |
Why?
|
| Bronchial Provocation Tests | 2 | 2004 | 9 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 652 | 0.020 |
Why?
|
| Ammonium Sulfate | 1 | 1988 | 6 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1988 | 101 | 0.020 |
Why?
|
| Methacholine Chloride | 2 | 1985 | 20 | 0.020 |
Why?
|
| Psychometrics | 1 | 2010 | 514 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2010 | 470 | 0.020 |
Why?
|
| Hippocampus | 1 | 2010 | 471 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 931 | 0.020 |
Why?
|
| Methods | 2 | 1985 | 156 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 1038 | 0.020 |
Why?
|
| p-Methoxy-N-methylphenethylamine | 1 | 1986 | 4 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 1196 | 0.020 |
Why?
|
| Calcimycin | 1 | 1986 | 32 | 0.020 |
Why?
|
| Carboxypeptidase B | 1 | 1986 | 1 | 0.020 |
Why?
|
| Carboxypeptidases A | 1 | 1986 | 2 | 0.020 |
Why?
|
| Phenylalanine | 1 | 1986 | 22 | 0.020 |
Why?
|
| Complement C4 | 2 | 1988 | 15 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1986 | 351 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1986 | 136 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1986 | 282 | 0.020 |
Why?
|
| Arginine | 1 | 1986 | 102 | 0.020 |
Why?
|
| Osteoarthritis | 1 | 1986 | 73 | 0.020 |
Why?
|
| Chemical Phenomena | 2 | 1979 | 62 | 0.020 |
Why?
|
| Protoporphyrins | 1 | 1985 | 10 | 0.020 |
Why?
|
| Chemistry | 2 | 1979 | 45 | 0.020 |
Why?
|
| Hemin | 1 | 1985 | 10 | 0.020 |
Why?
|
| Porphyrins | 1 | 1985 | 15 | 0.020 |
Why?
|
| Isoantibodies | 1 | 1985 | 35 | 0.020 |
Why?
|
| Heme | 1 | 1985 | 17 | 0.020 |
Why?
|
| Alpha-Globulins | 2 | 1976 | 18 | 0.020 |
Why?
|
| Enzymes, Immobilized | 1 | 1985 | 11 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1987 | 284 | 0.020 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2004 | 4 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 710 | 0.020 |
Why?
|
| Chemokine CCL11 | 1 | 2004 | 9 | 0.020 |
Why?
|
| Pigmentation Disorders | 1 | 1984 | 11 | 0.020 |
Why?
|
| Photosensitivity Disorders | 1 | 1984 | 7 | 0.020 |
Why?
|
| Interleukin-13 | 1 | 2004 | 16 | 0.020 |
Why?
|
| Erythema Multiforme | 1 | 1984 | 8 | 0.020 |
Why?
|
| Eczema | 1 | 1984 | 10 | 0.020 |
Why?
|
| Danazol | 1 | 1984 | 2 | 0.020 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2004 | 12 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 2004 | 35 | 0.020 |
Why?
|
| Tripelennamine | 1 | 1984 | 1 | 0.010 |
Why?
|
| Vocal Cords | 1 | 2004 | 18 | 0.010 |
Why?
|
| Plant Leaves | 1 | 2004 | 49 | 0.010 |
Why?
|
| Tissue Extracts | 1 | 1984 | 10 | 0.010 |
Why?
|
| Cimetidine | 1 | 1984 | 25 | 0.010 |
Why?
|
| Skin Temperature | 1 | 1984 | 24 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2010 | 824 | 0.010 |
Why?
|
| Odorants | 1 | 2004 | 52 | 0.010 |
Why?
|
| Laryngoscopy | 1 | 2004 | 61 | 0.010 |
Why?
|
| Trypsin Inhibitors | 2 | 1974 | 15 | 0.010 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2004 | 43 | 0.010 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1984 | 45 | 0.010 |
Why?
|
| Pancreatic Diseases | 1 | 1984 | 66 | 0.010 |
Why?
|
| Environment | 1 | 2004 | 115 | 0.010 |
Why?
|
| Dyspnea | 1 | 2004 | 87 | 0.010 |
Why?
|
| Menstruation | 1 | 1983 | 20 | 0.010 |
Why?
|
| Sulfonamides | 1 | 1984 | 141 | 0.010 |
Why?
|
| Food Hypersensitivity | 1 | 1983 | 20 | 0.010 |
Why?
|
| Complement Activating Enzymes | 1 | 1983 | 1 | 0.010 |
Why?
|
| Complement C1s | 1 | 1983 | 1 | 0.010 |
Why?
|
| Complement C1r | 1 | 1983 | 1 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1984 | 219 | 0.010 |
Why?
|
| Penicillins | 1 | 1983 | 32 | 0.010 |
Why?
|
| Complement Inactivator Proteins | 2 | 1973 | 20 | 0.010 |
Why?
|
| Saliva | 1 | 1984 | 142 | 0.010 |
Why?
|
| Gout | 1 | 1983 | 9 | 0.010 |
Why?
|
| Seasons | 1 | 1983 | 129 | 0.010 |
Why?
|
| Vasculitis | 1 | 1983 | 33 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1983 | 99 | 0.010 |
Why?
|
| Pancreas | 1 | 1984 | 225 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 1983 | 94 | 0.010 |
Why?
|
| Uric Acid | 1 | 1983 | 37 | 0.010 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 1984 | 148 | 0.010 |
Why?
|
| Factor VIIa | 1 | 1982 | 25 | 0.010 |
Why?
|
| Zea mays | 1 | 1982 | 27 | 0.010 |
Why?
|
| Plant Proteins | 1 | 1982 | 48 | 0.010 |
Why?
|
| Aspirin | 1 | 1983 | 295 | 0.010 |
Why?
|
| Eicosanoids | 1 | 2001 | 16 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 1981 | 87 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 425 | 0.010 |
Why?
|
| Bronchi | 1 | 2001 | 59 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2001 | 117 | 0.010 |
Why?
|
| Interleukins | 1 | 2001 | 79 | 0.010 |
Why?
|
| Endoscopy | 1 | 2004 | 464 | 0.010 |
Why?
|
| Cats | 1 | 2001 | 292 | 0.010 |
Why?
|
| Chemotactic Factors, Eosinophil | 1 | 1980 | 2 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1981 | 93 | 0.010 |
Why?
|
| Anilides | 1 | 1980 | 16 | 0.010 |
Why?
|
| Mathematics | 1 | 1980 | 83 | 0.010 |
Why?
|
| Sunlight | 1 | 1980 | 59 | 0.010 |
Why?
|
| Disulfides | 1 | 1980 | 40 | 0.010 |
Why?
|
| Biotransformation | 1 | 1980 | 69 | 0.010 |
Why?
|
| gamma-Globulins | 1 | 1979 | 8 | 0.010 |
Why?
|
| Angiotensin I | 1 | 1979 | 24 | 0.010 |
Why?
|
| Benzoates | 1 | 1979 | 20 | 0.010 |
Why?
|
| Atropine | 1 | 1979 | 29 | 0.010 |
Why?
|
| United States | 1 | 2011 | 7367 | 0.010 |
Why?
|
| Body Fluids | 1 | 1978 | 41 | 0.010 |
Why?
|
| Proteins | 2 | 1996 | 474 | 0.010 |
Why?
|
| Fractional Precipitation | 1 | 1977 | 2 | 0.010 |
Why?
|
| Chemical Precipitation | 1 | 1977 | 14 | 0.010 |
Why?
|
| Immune Complex Diseases | 1 | 1977 | 10 | 0.010 |
Why?
|
| Centrifugation | 1 | 1977 | 16 | 0.010 |
Why?
|
| Ultrafiltration | 2 | 1974 | 35 | 0.010 |
Why?
|
| Tissue Kallikreins | 1 | 1998 | 106 | 0.010 |
Why?
|
| Glycosaminoglycans | 1 | 1997 | 88 | 0.010 |
Why?
|
| SRS-A | 1 | 1976 | 20 | 0.010 |
Why?
|
| Antithrombin III | 1 | 1976 | 23 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 1996 | 10 | 0.010 |
Why?
|
| Integrin beta1 | 1 | 1996 | 48 | 0.010 |
Why?
|
| Nasal Lavage Fluid | 1 | 1996 | 4 | 0.010 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 1996 | 6 | 0.010 |
Why?
|
| Lactoferrin | 1 | 1996 | 6 | 0.010 |
Why?
|
| Muramidase | 1 | 1996 | 38 | 0.010 |
Why?
|
| Stem Cell Factor | 1 | 1995 | 39 | 0.010 |
Why?
|
| Protease Inhibitors | 2 | 1986 | 76 | 0.010 |
Why?
|
| Hepatitis B Antigens | 1 | 1975 | 1 | 0.010 |
Why?
|
| Syndrome | 1 | 1975 | 255 | 0.010 |
Why?
|
| Diamines | 1 | 1974 | 9 | 0.010 |
Why?
|
| Serotonin | 1 | 1975 | 144 | 0.010 |
Why?
|
| Adsorption | 1 | 1975 | 225 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1974 | 69 | 0.010 |
Why?
|
| Dialysis | 1 | 1973 | 30 | 0.010 |
Why?
|
| Cell Movement | 1 | 1996 | 630 | 0.010 |
Why?
|
| Cell Survival | 1 | 1996 | 901 | 0.010 |
Why?
|
| Uremia | 1 | 1993 | 10 | 0.010 |
Why?
|
| Aminocaproates | 1 | 1972 | 4 | 0.010 |
Why?
|
| Histidine | 1 | 1972 | 17 | 0.010 |
Why?
|
| Acrylic Resins | 1 | 1993 | 48 | 0.010 |
Why?
|
| Cellulose | 1 | 1993 | 22 | 0.010 |
Why?
|
| Polymers | 1 | 1974 | 244 | 0.010 |
Why?
|
| Serine | 1 | 1972 | 99 | 0.010 |
Why?
|
| Ketones | 1 | 1972 | 24 | 0.010 |
Why?
|
| Reference Values | 1 | 1993 | 579 | 0.010 |
Why?
|
| Methylcellulose | 1 | 1971 | 6 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 1988 | 19 | 0.010 |
Why?
|
| Drug Stability | 1 | 1988 | 71 | 0.010 |
Why?
|
| Lactates | 1 | 1988 | 29 | 0.010 |
Why?
|
| Blister | 1 | 1989 | 16 | 0.010 |
Why?
|
| Detergents | 1 | 1988 | 34 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1988 | 138 | 0.000 |
Why?
|
| Lactic Acid | 1 | 1988 | 86 | 0.000 |
Why?
|
| Leukemia | 1 | 1988 | 117 | 0.000 |
Why?
|
| Culture Techniques | 1 | 1986 | 65 | 0.000 |
Why?
|
| Antigens | 1 | 1986 | 90 | 0.000 |
Why?
|
| Drug Contamination | 1 | 1985 | 10 | 0.000 |
Why?
|
| Ileum | 1 | 1985 | 28 | 0.000 |
Why?
|
| Aerosols | 1 | 1985 | 42 | 0.000 |
Why?
|
| Prothrombin Time | 1 | 1985 | 24 | 0.000 |
Why?
|
| Antigens, Surface | 1 | 1985 | 71 | 0.000 |
Why?
|
| Muscle, Smooth | 1 | 1985 | 117 | 0.000 |
Why?
|
| Biological Assay | 1 | 1985 | 88 | 0.000 |
Why?
|
| Particle Size | 1 | 1985 | 201 | 0.000 |
Why?
|
| Amino Acids | 1 | 1985 | 131 | 0.000 |
Why?
|
| Ultraviolet Rays | 1 | 1985 | 130 | 0.000 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1983 | 36 | 0.000 |
Why?
|
| Lipopolysaccharides | 1 | 1985 | 455 | 0.000 |
Why?
|
| Crystallization | 1 | 1983 | 57 | 0.000 |
Why?
|
| Trypsin | 1 | 1981 | 64 | 0.000 |
Why?
|